Clinical Trials Directory

Trials / Completed

CompletedNCT02358473

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

Open-label, Multicenter Phase 1 Study of Mogamulizumab (KW-0761) in Combination With Docetaxel in Previously Treated Subjects With Non-small Cell Lung Cancer (NSCLC)

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
13 (actual)
Sponsor
Kyowa Kirin, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety of mogamulizumab in combination with docetaxel in adult subjects with previously treated locally advanced or metastatic non-small cell lung cancer.

Conditions

Interventions

TypeNameDescription
BIOLOGICALmogamulizumabMogamulizumab will be administered by IV infusion.
DRUGDocetaxelDocetaxel will be administered by IV infusion.

Timeline

Start date
2015-01-01
Primary completion
2016-12-01
Completion
2016-12-01
First posted
2015-02-09
Last updated
2024-09-19
Results posted
2018-11-30

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02358473. Inclusion in this directory is not an endorsement.